AllianceBernstein
AMBI

AllianceBernstein’s Ambit Biosciences Corp AMBI Stock Holding History

AllianceBernstein’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-426
Closed -$4K – 3863
2014
Q1 		$4K Buy
426
+282
+196% +$2.99K ﹤0.01% 3360
2013
Q4 		$1K Hold
144
– – ﹤0.01% 3426
2013
Q3 		$2K Buy
+144
New +$1.91K ﹤0.01% 3325

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein's AMBI Position: Q2 2014 in Review

AllianceBernstein sold out of Ambit Biosciences Corp (AMBI) in Q2 2014, closing a stake of 426 shares — an estimated $4K sold.

AllianceBernstein first reported a position in AMBI in Q3 2013 and held it in 3 quarters. The position peaked at $4K in Q1 2014. 36 funds tracked by Wall St. Rank hold AMBI as of Q2 2014.

  • AllianceBernstein reported no remaining Ambit Biosciences Corp position as of Q2 2014 after selling out during the quarter.
  • AllianceBernstein sold 426 Ambit Biosciences Corp shares in Q2 2014, an estimated $4K.
  • AllianceBernstein first reported a position in Ambit Biosciences Corp in Q3 2013 and held it in 3 quarters.
  • AllianceBernstein's Ambit Biosciences Corp position peaked at $4K in Q1 2014.
  • 36 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q2 2014.

Based on AllianceBernstein's 13F filing for Q2 2014, filed 13 Aug 2014.